ES2040234T3 - Derivados del tetrahidronaftaleno y medicamentos que los contienen. - Google Patents

Derivados del tetrahidronaftaleno y medicamentos que los contienen.

Info

Publication number
ES2040234T3
ES2040234T3 ES198787116251T ES87116251T ES2040234T3 ES 2040234 T3 ES2040234 T3 ES 2040234T3 ES 198787116251 T ES198787116251 T ES 198787116251T ES 87116251 T ES87116251 T ES 87116251T ES 2040234 T3 ES2040234 T3 ES 2040234T3
Authority
ES
Spain
Prior art keywords
formula
medicines
tetrahidronaftaleno
derivatives
contain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787116251T
Other languages
English (en)
Inventor
Quirico Dr. Branca
Roland Prof. Dr. Jaunin
Hans Peter Dr. Marki
Franzi Dr. Marti
Henri Prof. Dr. Ramuz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2040234T3 publication Critical patent/ES2040234T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Luminescent Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Organic Insulating Materials (AREA)
  • Hydrogenated Pyridines (AREA)
  • Steroid Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE VERIFICARIA QUE EL NUEVO DERIVADO DE TETRAHIDRONAFTALIN DE LA FORMULA DONDE LOS SIMBOLOS A,X,N,R,R1,R2 Y R3 QUE POSEEN UN SIGNIFICADO DADO EN LA DEMANDA 1, TIENEN UN EFECTO ANTIARRITMICO Y MARCADAMENTE ANTAGONISTICO DE CALCIO Y PUEDEN UTILIZARSE POR CONSIGUIENTE COMO MEDICAMENTOS, ESPECIALMENTE PARA LA LUCHA O PREVENCION DE LA ANGINA DE PECHO, ISQUEMIA, ARRITMIA, ALTA PRESION DE SANGRE E INSUFICIENCIA CARDIACA. LAS COMBINACIONES DE LA FORMULA I PUEDEN FABRICARSE POR AMINACION DE UNA COMBINACION DE LA FORMULA, CON UNA AMINA DE ALQUIL N CORRESPONDIENTE Y DADO EL CASO ACILIACION O CONSIGUIENTE O TRANSFORMACION CON UN ISOCIANATO Y OXIDACION N.
ES198787116251T 1986-11-14 1987-11-04 Derivados del tetrahidronaftaleno y medicamentos que los contienen. Expired - Lifetime ES2040234T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH456586 1986-11-14

Publications (1)

Publication Number Publication Date
ES2040234T3 true ES2040234T3 (es) 1993-10-16

Family

ID=4278454

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198787116251T Expired - Lifetime ES2040234T3 (es) 1986-11-14 1987-11-04 Derivados del tetrahidronaftaleno y medicamentos que los contienen.

Country Status (31)

Country Link
US (1) US4808605A (es)
EP (1) EP0268148B1 (es)
JP (1) JP2504490B2 (es)
KR (1) KR960004863B1 (es)
CN (1) CN1028991C (es)
AT (1) ATE70267T1 (es)
AU (1) AU600769B2 (es)
BG (1) BG60937B2 (es)
CA (1) CA1319144C (es)
CS (2) CS264350B2 (es)
DE (2) DE3775177D1 (es)
DK (1) DK171349B1 (es)
DZ (1) DZ1142A1 (es)
ES (1) ES2040234T3 (es)
FI (1) FI94414C (es)
GR (1) GR3004029T3 (es)
HK (1) HK110494A (es)
HU (1) HU215915B (es)
IE (1) IE60695B1 (es)
IL (1) IL84407A (es)
LV (1) LV5745B4 (es)
MC (1) MC1883A1 (es)
MX (1) MX173614B (es)
NL (1) NL970019I2 (es)
NO (2) NO172237C (es)
NZ (1) NZ222474A (es)
PH (1) PH23919A (es)
PT (1) PT86130B (es)
SG (1) SG114194G (es)
ZA (1) ZA878362B (es)
ZW (1) ZW20087A1 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2003283A1 (en) * 1988-12-05 1990-06-05 C. Anne Higley Imidazoles for the treatment of atherosclerosis
CA2011461A1 (en) * 1989-03-20 1990-09-20 Urs Hengartner Tetrahydronaphthalene derivatives
NL9001522A (nl) * 1990-07-04 1992-02-03 Schreiner Luchtvaart Werkwijze voor het vervaardigen van een voorwerp bestaande uit een schuimkern en eventueel een of meer afdeklagen.
TW216770B (es) * 1991-07-23 1993-12-01 Hoffmann La Roche
US5663166A (en) * 1991-10-18 1997-09-02 Genentech, Inc. Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor
US5250679A (en) * 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
CN1088062C (zh) * 1994-11-23 2002-07-24 纽罗根公司 某些4－氨基甲基－2－取代的咪唑衍生物2－氨基甲基－4－取代的咪唑衍生物新的一族多巴胺受体亚型特异性配体
EP0750006B1 (en) 1995-06-23 2002-03-27 Technische Universiteit Delft Method of making a foamable film
US5910606A (en) 1996-01-31 1999-06-08 Hoffmann-La Roche Inc. Process for making α,β-unsaturated carboxylic acids
US5811556A (en) * 1997-04-30 1998-09-22 Roche Colorado Corporation Preparation of mibefradil via a naphthalenylacetic acid
US5808088A (en) * 1997-04-30 1998-09-15 Roche Colorado Corporation Preparation of mibefradil via an acetamide anion
US5811557A (en) * 1997-04-30 1998-09-22 Roche Colorado Corporation Preparation of mibefradil via an acetonitrile anion
US6897305B2 (en) * 1998-06-08 2005-05-24 Theravance, Inc. Calcium channel drugs and uses
US7101909B2 (en) * 1998-10-12 2006-09-05 Theravance, Inc. Calcium channel drugs and uses
HUP0202143A3 (en) * 1999-07-28 2003-12-29 Ortho Mcneil Pharm Inc Amine and amide derivatives as ligands for the neuropeptide y y5 receptor pharmaceutical compositions containing them and their use
WO2001062741A1 (en) * 2000-02-25 2001-08-30 South Alabama Medical Science Foundation Tetrahydronaphtalene derivatives and their use
WO2001062740A1 (en) * 2000-02-25 2001-08-30 South Alabama Medical Science Foundation Mibefradil analogues and their use
ES2274854T3 (es) * 2000-05-08 2007-06-01 Pfizer Products Inc. Resolucion enzimatica de moduladores selectivos del receptor de estrogeno.
FR2827862A1 (fr) * 2001-07-27 2003-01-31 Lipha Derives imidazolylalkylarylalcanoiques et leurs applications en therapeutique
US6608097B2 (en) 2001-10-10 2003-08-19 Aryx Therapeutics Materials and methods for the treatment of hypertension and angina
KR20030037081A (ko) 2001-11-02 2003-05-12 한국과학기술연구원 Ｔ 타입 칼슘채널을 조절하여 복통을 억제하는 방법
EP1545519B1 (en) 2002-08-19 2011-03-23 Pfizer Inc. Combination therapy for hyperproliferative diseases
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
PT1660491E (pt) * 2003-07-28 2008-10-10 Janssen Pharmaceutica Nv Derivados de benzimidazole, benzotiazole e benzoxazole e a sua utilização como moduladores de lta4h
EP1796653A2 (en) * 2004-07-26 2007-06-20 Actelion Pharmaceuticals Ltd. Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7893050B2 (en) * 2005-10-26 2011-02-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
EP2351569B1 (en) 2005-10-26 2012-08-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
JP5498168B2 (ja) 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
CL2008000468A1 (es) * 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Uso de compuestos derivados de heterociclos, inhibidores de leucotrina a4 hidrolasa (lta4h), utiles para tratar o prevenir la dermatitis, acne, infarto al miocardio, dolor, picazon, gingivitis, cancer, artritis, entre otras.
SI2152670T1 (sl) * 2007-04-27 2014-04-30 Actelion Pharmaceuticals Ltd. Premoščene šestčlenske obročne spojine
CA2721099C (en) * 2008-04-11 2017-04-25 Janssen Pharmaceutica Nv Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene a4 hydrolase
US20110039905A1 (en) * 2008-04-25 2011-02-17 Francis Hubler Benzimidazole derivatives as calcium channel blockers
US8314253B2 (en) 2008-10-22 2012-11-20 Actelion Pharmaceuticals Ltd. Bridged tetrahydronaphthalene derivatives
WO2010046729A2 (en) * 2008-10-23 2010-04-29 Actelion Pharmaceuticals Ltd Tetrahydronaphthalene compounds
EP2995303A1 (en) 2009-07-10 2016-03-16 President and Fellows of Harvard College Permanently charged sodium and calcium channel blockers as anti-inflammatory agents
US8513434B2 (en) 2010-03-02 2013-08-20 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
US8575361B2 (en) 2010-03-02 2013-11-05 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
US8883844B2 (en) 2010-09-24 2014-11-11 Nitrogenix Inc. Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
SG11201507496UA (en) 2013-04-17 2015-11-27 Pfizer N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
ES2936400T3 (es) 2015-10-22 2023-03-16 Cavion Inc Métodos para tratar el síndrome Angelman
WO2018152317A1 (en) * 2017-02-15 2018-08-23 Cavion, Inc. Calcium channel inhibitors
KR102654466B1 (ko) 2017-04-26 2024-04-08 카비온, 인코포레이티드 기억 및 인지 개선 방법 및 기억 및 인지 장애 치료 방법
TW202602439A (zh) 2018-10-03 2026-01-16 美商卡凡恩公司 以(r)-2-(4-異丙基苯基)-n-(1-(5-(2,2,2-三氟乙氧基)吡啶-2-基)乙基)乙醯胺治療自發性震顫
US11248001B2 (en) 2019-01-18 2022-02-15 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
CN115850119A (zh) * 2022-11-26 2023-03-28 南昌大学 一种2-氯芳香胺类化合物的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914216A (en) * 1962-12-18 1975-10-21 Boehringer Sohn Ingelheim 1-Phenyl-3H-1,4-benzodiazepine-2,5-(1H,4H)-diones
BE793460A (fr) * 1971-12-29 1973-06-28 Boehringer Sohn Ingelheim Nouvelles 1-aryl-3h,1,4-benzodiazepine-2,5-(1h
NZ213651A (en) * 1984-10-11 1989-07-27 Hoffmann La Roche Tetrahydronapthalene derivatives and medicaments

Also Published As

Publication number Publication date
GR3004029T3 (es) 1993-03-31
LV5745A4 (lv) 1996-10-20
JPS63139171A (ja) 1988-06-10
CS787487A2 (en) 1988-11-15
NO172237B (no) 1993-03-15
CS394891A3 (en) 1992-06-17
FI94414B (fi) 1995-05-31
JP2504490B2 (ja) 1996-06-05
FI94414C (fi) 1995-09-11
DK559987D0 (da) 1987-10-26
IE60695B1 (en) 1994-08-10
DZ1142A1 (fr) 2004-09-13
FI875024A0 (fi) 1987-11-13
BG60937B2 (bg) 1996-06-28
CA1319144C (en) 1993-06-15
MX173614B (es) 1994-03-18
PT86130B (pt) 1990-11-20
NL970019I2 (nl) 1997-11-03
PT86130A (en) 1987-12-01
CN1028991C (zh) 1995-06-21
HUT60251A (en) 1992-08-28
AU8090987A (en) 1988-05-19
FI875024A7 (fi) 1988-05-15
NZ222474A (en) 1990-02-26
DK559987A (da) 1988-05-15
IL84407A (en) 1991-09-16
EP0268148A1 (de) 1988-05-25
NO874757L (no) 1988-05-16
NL970019I1 (nl) 1997-08-01
MX9271A (es) 1993-09-01
LV5745B4 (lv) 1996-12-20
DE19775076I2 (de) 2001-08-09
DK171349B1 (da) 1996-09-16
IE873070L (en) 1988-05-14
KR880006163A (ko) 1988-07-21
SG114194G (en) 1994-11-25
CN87107875A (zh) 1988-05-25
CS264350B2 (en) 1989-07-12
HU215915B (hu) 1999-03-29
AU600769B2 (en) 1990-08-23
NO1998001I1 (no) 1998-01-09
NO874757D0 (no) 1987-11-13
HK110494A (en) 1994-10-21
MC1883A1 (fr) 1989-01-24
IL84407A0 (en) 1988-04-29
US4808605A (en) 1989-02-28
PH23919A (en) 1990-01-23
EP0268148B1 (de) 1991-12-11
NO172237C (no) 1993-06-23
ZW20087A1 (en) 1988-07-20
ZA878362B (en) 1988-05-16
DE3775177D1 (de) 1992-01-23
KR960004863B1 (en) 1996-04-16
ATE70267T1 (de) 1991-12-15

Similar Documents

Publication Publication Date Title
ES2096614T3 (es) Derivados de acidos biliares, procedimiento para su preparacion y utilizacion de este compuesto como medicamento.
ES2059207T3 (es) Procedimiento para la preparacion de derivados del taxano, nuevos derivados obtenidos y composiciones farmaceuticas que les contienen.
ES2113867T3 (es) Imino-derivados ciclicos, medicamentos que contienen estos compuestos y procedimiento para su preparacion.
ES2152222T3 (es) Sulfonamidas, su preparacion y su uso como medicamento e intermedio.
ES2054860T5 (es) Derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion y su utilizacion como medicamentos.
BR9714164A (pt) Novos derivados de ácido fluoracrìlico, novas misturas de herbicidas e antìdotos e seu emprego
BR0207726A (pt) Sais farmacêuticos
ES2146741T3 (es) Derivados de rapamicina utiles como inmunosupresores.
ES2078905T3 (es) Nuevos compuestos heterociclicos condensados y su utilizacion para medicamentos.
ES2039269T3 (es) Derivados de azolilmetil-ciclopropilo.
ES2192201T3 (es) Compuestos de piranona utiles para el tratamiento de infecciones retrovirales.
MX9303158A (es) Derivados de aminoquinolona substituidos con grupoarilo o con un grupo heterociclico aromatico; y agente anti-vih.
ES2179094T3 (es) Derivados de amidas ciclicas como antagonistas de la neuroquinina a.
MX9301129A (es) Nuevas ciclosporinas y composiciones farmaceuticas que las contienen.
ES2058093T3 (es) Agentes herbicidas y fungicidas a base de derivados de pirazolin-5-ona substituidos.
ES477353A1 (es) Un procedimiento para la preparacion de nuevas acil-anilinasde actividad fungicidas.
ES2085924T3 (es) Compuestos quelatantes y su utilizacion.
MX9100607A (es) Compuesto triciclico novedoso o sales del mismo,metodo para producir el mismo y agente antimicrobiano que lo contiene
MX9307232A (es) Arilcicloalquilaminas n,n-disustituidas, sus sales, medicamentos que contiene estos compuestos y su empleo, asi como procedimientos para su preparacion.
ES2173883T3 (es) Utilizacion de derivados de piperacina-acetamida contra los daños de reperfusion.
MX9304424A (es) Bencimidazoles, medicamentos que contienen estos compuestos y procedimiento para su preparacion.
MX9303123A (es) Ciclopentano-y-penteno-beta-aminoacidos, procedimiento para su preparacion y medicamentos que los contienen.
ES2116612T3 (es) Nuevas bis-naftalimidas para el tratamiento del cancer.
ES2029879T3 (es) Procedimiento para producir derivados de aminas sustituidas.
ES2150461T3 (es) Derivados de amidinofenilalanina, proceso para su preparacion, su empleo y agentes que los contienen como anticoagulantes.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 268148

Country of ref document: ES